DEF: Bolt Biotherapeutics Proposes Reverse Stock Split to Regain Nasdaq Compliance

Bolt Biotherapeutics is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing.

Summary

• Bolt Biotherapeutics is convening its 2025 Annual Meeting of Stockholders on May 27, 2025, to address several key proposals.
• The proposals include the election of two Class I directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and approval of an amendment to the certificate of incorporation to effect a reverse stock split.
• The reverse stock split aims to increase the company's stock price to comply with Nasdaq's minimum bid requirement of $1.00 per share.
• The proposed reverse stock split ratio ranges from 1-for-10 to 1-for-25, to be determined at the discretion of the Board of Directors.
• As of April 15, 2025, there were 38,339,697 shares of common stock outstanding and entitled to vote.
• The Board recommends voting FOR all proposals.

Sentiment

Score: 6

Explanation: The document is primarily procedural, outlining the proposals for the upcoming annual meeting. While the need for a reverse stock split indicates underlying challenges, the document focuses on the steps being taken to address them, resulting in a neutral to slightly positive sentiment.

Positives

• The proposed reverse stock split aims to maintain the company's listing on the Nasdaq Capital Market, which is considered more accessible and efficient than OTC markets.
• Maintaining the Nasdaq listing may enhance the company's access to capital and increase flexibility in strategic or financing transactions.
• The Board believes a higher stock price resulting from the reverse stock split could encourage institutional investor interest.

Negatives

• The company is currently not in compliance with the Nasdaq Minimum Bid Requirement.
• There is no guarantee that the reverse stock split will increase the stock price proportionally or result in a permanent increase.
• A reverse stock split may result in some stockholders owning odd lots of less than 100 shares, which can be more difficult to sell.

Risks

• The market price of the common stock is dependent on many factors, including the company's business and financial performance, general market conditions, and prospects for future growth.
• Even if the reverse stock split is approved and effected, there is no assurance that the company will continue to meet the continued listing requirements of the Nasdaq Capital Market.
• The reduced number of shares outstanding after the reverse stock split could adversely affect liquidity.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements through the proposed reverse stock split and maintain its listing on the Nasdaq Capital Market.

Management Comments

• The Board believes that the consummation of the Reverse Stock Split is the best way to maintain liquidity by achieving compliance with the Nasdaq Minimum Bid Requirement.
• The Board also believes that the current low per share market price of the common stock has a negative effect on the marketability of our existing shares.

Industry Context

Many biotech companies facing similar stock price challenges have implemented reverse stock splits to maintain exchange listings and attract institutional investors.

Comparison to Industry Standards

• Other biotech companies, such as XOMA Corporation and BioCryst Pharmaceuticals, have previously implemented reverse stock splits to regain Nasdaq compliance.
• The success of a reverse stock split in increasing and sustaining a company's stock price varies depending on the company's underlying fundamentals and market conditions.
• The proposed reverse stock split ratio of 1-for-10 to 1-for-25 is within the typical range for companies seeking to regain Nasdaq compliance.

Stakeholder Impact

• Shareholders may experience a change in the number of shares they own due to the reverse stock split.
• The reverse stock split aims to improve the company's standing in the market, potentially benefiting all stakeholders.
• The company's ability to maintain its Nasdaq listing is crucial for investor confidence and access to capital.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 27, 2025.
• If approved, the Board will determine the final reverse stock split ratio and file an amendment to the certificate of incorporation.
• The company will notify stockholders of the effective date of the reverse stock split.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, annual meeting, proxy statement, stockholders, directors, PricewaterhouseCoopers, listing requirements, common stock, Bolt Biotherapeutics